FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
Open Access
- 12 May 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (11), 1739-1745
- https://doi.org/10.1038/sj.bjc.6605076
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- RNA sequencing: advances, challenges and opportunitiesNature Reviews Genetics, 2010
- Over-expression of the IGI1 leading to altered shoot-branching development related to MAX pathway in ArabidopsisPlant Molecular Biology, 2010
- cis-Element- and Transcriptome-Based Screening of Root Hair-Specific Genes and Their Functional Characterization in ArabidopsisPlant Physiology, 2009
- Evolutionary History and Stress Regulation of Plant Receptor-Like Kinase/Pelle GenesPlant Physiology, 2009
- Auxin transport through non-hair cells sustains root-hair developmentNature, 2008
- Omics-based identification of Arabidopsis Myb transcription factors regulating aliphatic glucosinolate biosynthesisProceedings of the National Academy of Sciences of the United States of America, 2007
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- Expression dynamics of a cellular metabolic networkMolecular Systems Biology, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000